A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)
Key facts
- Who runs it
- Mirum Pharmaceuticals, Inc.
- Where
- Aurora, Boston, Cleveland, Coronado, Dallas, Detroit, Durham, Hixson, Houston, Jackson, Lakewood Rch, Los Angeles, Manhasset, Miami, Morrisville, Nashville, New York, Newport News, Philadelphia, Pittsburgh, Richmond, Rochester, Sacramento, Salt Lake City, San Francisco, Seattle, Tampa, and Washington D.C., United StatesSee the 34 sitesAlso in 13 other countries, 69 sites
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 182 people enrolled
- Started
- 18 Dec 2020
- Expected to end
- Mar 2028
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Volixibat
- Placebo
- Record updated
- 19 October 2026
Who can take part
- Age
- 12 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Provide freely signed informed consent and assent (as applicable) and be willing to comply with all study visits and requirements through end of study, including the follow-up period
- Subjects aged ≥12 years for eligible regions; otherwise ≥18 years
- Confirmed diagnosis of large duct or small duct PSC based on American Association for the Study of Liver Disease (AASLD) guidelines
- Pruritus associated with PSC as assessed by Adult ItchRO
- Ursodeoxycholic acid (UDCA) and anti-pruritic medication use will be allowed if meeting additional criteria
- Concomitant Inflammatory Bowel Disease (IBD) is allowed if meeting additional criteria
Who cannot take part
- Evidence or clinical suspicion of decompensated cirrhosis, or a history of decompensation events
- History of ileostomy or small bowel surgery/resection or other surgeries that may have disrupted the enterohepatic circulation
- Evidence, history, or suspicion of other liver disease; PSC patients with AIH are not excluded
- History of liver transplantation
- Exceeding pre-defined biochemical values for alanine aminotransferase/aspartate aminotransferase (ALT/AST), estimated glomerular filtration rate (eGFR),serum creatinine (sCr), platelet count, international normalized ratio (INR) and total bilirubin
- Pruritus associated with an etiology other than PSC
- Bile duct stent or percutaneous bile duct drain placement, or balloon dilatation procedure of a stricture within 12 weeks of Screening
Where in United States
Also in 13 other countries, 69 sites
- University of Colorado Anschutz Medical CampusAurora, United States
- Beth Israel Deaconess Medical CenterBoston, United States
- Cleveland ClinicCleveland, United States
- Southern California Research CenterCoronado, United States
- The Liver Institute at Methodist Dallas Medical CenterDallas, United States
- University of Texas Southwestern Medical CenterDallas, United States
- Henry Ford HospitalDetroit, United States
- Duke Health - Duke University Medical CenterDurham, United States
- Galen Medical GroupHixson, United States
- Houston Methodist HospitalHouston, United States
- Liver Associates of TexasHouston, United States
- Southern Therapy and Advanced Research LLCJackson, United States
- Florida Research InstituteLakewood Rch, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- Northwell HealthManhasset, United States
- University of Miami - Schiff Center for Liver DiseasesMiami, United States
- Science 37, Inc (Remote-homebased Telemedicine)Morrisville, United States
- Vanderbilt University Medical CenterNashville, United States
- Columbia University Medical Center - Presbyterian Hospital and Vanderbilt ClinicNew York, United States
- New York University Langone HealthNew York, United States
- Weill Cornell Medical CollegeNew York, United States
- Bon Secours Liver Institution of Hampton Roads Mary Immaculate Hospital OfficeNewport News, United States
- Einstein Healthcare Network - Einstein Medical CenterPhiladelphia, United States
- University of Pittsburgh Medical CenterPittsburgh, United States
- Richmond Community Hospital LLCRichmond, United States
- Mayo ClinicRochester, United States
- University of Rochester Medical Center - Strong Memorial HospitalRochester, United States
- University of California - DavisSacramento, United States
- University of Utah Health CareSalt Lake City, United States
- California Pacific Medical Center Research InstituteSan Francisco, United States
- Liver Institute NorthwestSeattle, United States
- University of Washington - Harborview Medical CenterSeattle, United States
- Tampa General HospitalTampa, United States
- MedStar Georgetown University HospitalWashington D.C., United States
About the trial
What the trial wants to find out
The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Sclerosing Cholangitis (PSC), and to assess the possible impact on the disease progression of PSC.
The 5 groups in the trial
- Part 1 Arm 1: Volixibat 20mgTreatment being tested
Participants randomized to this arm will receive volixibat 20mg twice daily.
Treatment: Volixibat
- Part 1 Arm 2: Volixibat 80mgTreatment being tested
Participants randomized to this arm will receive volixibat 80mg twice daily.
Treatment: Volixibat
- Part 1 Arm 3: PlaceboPlacebo, for comparison
Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
Treatment: Placebo
- Part 2 Arm 1: Volixibat Selected Dose 20mgTreatment being tested
Participants randomized to this arm will receive volixibat 20mg twice daily.
Treatment: Volixibat
- Part 2 Arm 2: PlaceboPlacebo, for comparison
Participants in this arm will receive capsules matched to the study drug minus the active volixibat substance, twice daily.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
- Record updated
- 19 October 2026